Skip to main content
Signal8
Launch Terminal

Tectonic Therapeutic, Inc. (TECX)

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Tectonic Therapeutic, Inc. logo

Tectonic Therapeutic, Inc.

NASDAQ:TECXHealthcare
-3.51%$19.78
AH$19.78+0.00%vs close
Mkt Cap$386.69M
Float11.63M
O/S19.55M
Vol
$ Vol
RVOL
Inst Own71.7%
SI19.1%
Earnings
Dilution
Tectonic Therapeutic, Inc. logoNASDAQ:TECX$19.78-3.51%
Phase Distribution
6 lead-sponsored trials·1 active·0 completed
Phase 1/22
Phase 21
Phase 2/31
Not applicable2
Status Overview
Active, not recruiting1
Stopped5

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2/3
    Withdrawn

    An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

    Gene therapy, Enzyme Replacement Agent

    Gaucher Disease, Type 3

    Enrollment
    0
    Start
    Oct 2023est.
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT05815004
  • Phase 2
    Active, not recruiting

    A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

    TX000045- Dose A, TX000045- Dose B

    Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

    Enrollment
    191
    Start
    Sep 2024
    Primary Completion
    Nov 2026est.
    Completion
    Jan 2027est.
    NCT06616974
  • Phase 1/2
    Terminated

    Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease

    AVR-RD-01

    Fabry Disease

    Enrollment
    15
    Start
    Feb 2018
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT03454893
  • Phase 1/2
    Terminated

    Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease

    AVR-RD-02

    Gaucher Disease

    Enrollment
    8
    Start
    May 2019
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT04145037
  • Observational
    Terminated

    A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02

    Safety and efficacy assessments

    Type 1 Gaucher Disease

    Enrollment
    4
    Start
    Jul 2021
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT04836377
  • Observational
    Terminated

    Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201

    Safety and Efficacy Assessments

    Fabry Disease

    Enrollment
    5
    Start
    May 2019
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT04999059
Search ClinicalTrials.gov for “Tectonic Therapeutic”